Merck KGaA

Merck KGaA lands rights to 3rd F-star oncology bispecific antibody
Merck KGaA lands rights to 3rd F-star oncology bispecific antibody
Fierce Biotech
Merck KGaA
F-star Therapeutics
immuno-oncology
bispecific antibodies
Flag link:
GSK, Merck KGaA's BTC Drug Fails for Second Time This Year
GSK, Merck KGaA's BTC Drug Fails for Second Time This Year
BioSpace
Merck KGaA
GSK
metastatic biliary tract cancer
bintrafusp alfa
Flag link:
Merck KGaA foresees post-pandemic localization of biologics supply chains
Merck KGaA foresees post-pandemic localization of biologics supply chains
Biopharma Reporter
Merck KGaA
COVID-19
pandemic
supply chain
Flag link:
Merck KGaA to Consolidate Its Silicon Valley Innovation Sites
Merck KGaA to Consolidate Its Silicon Valley Innovation Sites
BioSpace
Merck KGaA
Silcon Valley
innovation
Flag link:
Merck KGaA pens $855M upfront, biobucks pact with Debiopharm for next-gen cancer asset
Merck KGaA pens $855M upfront, biobucks pact with Debiopharm for next-gen cancer asset
Fierce Biotech
Merck KGaA
Debiopharm
biobucks
Bavencio
Debio1143
xevinapant
Flag link:
Merck KGaA offloads clinical-phase cancer drugs to Day One
Merck KGaA offloads clinical-phase cancer drugs to Day One
Fierce Biotech
Merck KGaA
Day One Biopharmaceuticals
pimasertib
solid tumors
Flag link:
Pharma’s pipeline continues to provide drama as investors look beyond COVID in Q4
Pharma’s pipeline continues to provide drama as investors look beyond COVID in Q4
Pharmaforum
pharma industry
R&D
pandemic
earnings
COVID-19
Biogen
GW Pharma
Jazz Pharmaceuticals
GSK
Merck KGaA
Flag link:
BioNTech Gets Help From Merck KGaA in Move to Speed Covid Shots
BioNTech Gets Help From Merck KGaA in Move to Speed Covid Shots
Bloomberg
Merck KGaA
BioNTech
COVID-19
vaccines
Flag link:
FDA Approves Merck KGaA's Tepmetko for Aggressive Lung Cancer
FDA Approves Merck KGaA's Tepmetko for Aggressive Lung Cancer
BioSpace
Merck KGaA
Tepmetko
FDA
metastatic non-small cell lung cancer
Flag link:
GSK, German Merck's $4.2B bintrafusp alfa drug a bust, fails to beat king Keytruda in lung cancer
GSK, German Merck's $4.2B bintrafusp alfa drug a bust, fails to beat king Keytruda in lung cancer
Fierce Biotech
GSK
Merck KGaA
bintrafusp alfa
clinical trial
Merck
Keytruda
Flag link:
Ex-Gilead execs bag $80M to trial drug licensed from Merck KGaA
Ex-Gilead execs bag $80M to trial drug licensed from Merck KGaA
Fierce Biotech
Vera Therapeutics
Merck KGaA
clinical trials
kidney disease
atacicept
Gilead Sciences
Flag link:
Better Together – Merck KGaA Announces Collaboration with Artios
Better Together – Merck KGaA Announces Collaboration with Artios
BioSpace
Merck KGaA
Artios Pharma
drug development
cancer
oncology
Flag link:
Merck KGaA Diversifies with First Female CEO
Merck KGaA Diversifies with First Female CEO
BioSpace
Merck KGaA
Female Executives
Pharma CEOs
Belén Garijo
Flag link:
ESMO: Pfizer, Merck KGaA's Bavencio comes up short against placebo in risky head and neck cancer trial
ESMO: Pfizer, Merck KGaA's Bavencio comes up short against placebo in risky head and neck cancer trial
Fierce Pharma
ESMO
Pfizer
Merck KGaA
Bavencio
head and neck cancer
clinical trials
Flag link:
Merck KGaA : to Invest EUR59 Million to Expand Pharmaceutical Manufacturing at US Facility
Merck KGaA : to Invest EUR59 Million to Expand Pharmaceutical Manufacturing at US Facility
Market Screener
drug manufacturing
Merck KGaA
Flag link:
Big pharma spinouts grow up
Big pharma spinouts grow up
EP Vantage
Big Pharma
spinoffs
Merck KGaA
Pfizer
GSK
Novartis
Roche
Sanofi
JNJ
AstraZeneca
Flag link:
FDA starts quick review of Merck KGaA’s MET-targeting lung cancer drug
FDA starts quick review of Merck KGaA’s MET-targeting lung cancer drug
Pharmaforum
Merck KGaA
MET inhibitors
tepotinib
lung cancer
Flag link:
Merck KGaA picks up another anticancer bispecific from F-star
Merck KGaA picks up another anticancer bispecific from F-star
Fierce Biotech
Merck KGaA
F-star Therapeutics
immuno-oncology
bispecific antibodies
Flag link:
Merck KGaA's manufacturing group could see billions from COVID-19 work: analyst
Merck KGaA's manufacturing group could see billions from COVID-19 work: analyst
Fierce Pharma
COVID-19
vaccines
drug manufacturing
Merck KGaA
Flag link:
Merck KGaA’s ATR cancer drug cleared for further trials after phase 1 trial success
Merck KGaA’s ATR cancer drug cleared for further trials after phase 1 trial success
Pharmaforum
Merck KGaA
cancer
clinical trials
DNA repair
Flag link:

Pages